• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Dabigatran, A Direct Thrombin Inhibitor, In Atrial Fibrillation: Is It Already Time For A Change In Oral Anticoagulation Therapy?达比加群，一种直接凝血酶抑制剂，用于心房颤动：口服抗凝治疗是否已到改变之时？
J Atr Fibrillation. 2010 Jan 1;2(4):234. doi: 10.4022/jafib.234. eCollection 2010 Jan-Feb.
2
Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.达比加群酯，一种新型的口服直接凝血酶抑制剂，用于预防心房颤动患者的中风。
Expert Opin Pharmacother. 2010 Jun;11(8):1403-11. doi: 10.1517/14656566.2010.482931.
3
Dabigatran etexilate: A novel oral direct thrombin inhibitor.达比加群酯：一种新型口服直接凝血酶抑制剂。
Am J Health Syst Pharm. 2011 Aug 15;68(16):1506-19. doi: 10.2146/ajhp100348.
4
Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.达比加群酯：一种用于预防和治疗血栓栓塞性疾病的口服直接凝血酶抑制剂。
Pharmacotherapy. 2008 Nov;28(11):1354-73. doi: 10.1592/phco.28.11.1354.
5
Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.抗凝治疗新进展：关注达比加群，一种口服直接凝血酶抑制剂。
J Cardiothorac Vasc Anesth. 2011 Dec;25(6):1208-12. doi: 10.1053/j.jvca.2011.08.005. Epub 2011 Oct 7.
6
[Direct oral thrombin inhibitor, "dabigatran"].[直接口服凝血酶抑制剂，“达比加群”]
Nihon Rinsho. 2013 Jan;71(1):113-8.
7
Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies.达比加群在伴有非瓣膜性心房颤动和肝素-PF4 抗体的冠状动脉旁路手术后患者中的应用。
Ann Pharmacother. 2012 Jan;46(1):e3. doi: 10.1345/aph.1Q474. Epub 2011 Dec 27.
8
Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience.达比加群用于非瓣膜性心房颤动：从临床试验到现实生活经验
J Cardiovasc Med (Hagerstown). 2017 Jul;18(7):467-477. doi: 10.2459/JCM.0000000000000524.
9
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.经皮冠状动脉介入治疗（PCI）后伴有心房颤动患者的口服抗凝药物转换：RE-DUAL PCI 试验亚组分析。
JACC Cardiovasc Interv. 2019 Dec 9;12(23):2331-2341. doi: 10.1016/j.jcin.2019.08.039.
10
Neurosurgical complications of direct thrombin inhibitors--catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran.直接凝血酶抑制剂的神经外科并发症——接受达比加群治疗的患者在轻度创伤性脑损伤后发生灾难性出血。
J Neurosurg. 2012 May;116(5):1093-6. doi: 10.3171/2012.2.JNS112132. Epub 2012 Mar 6.

本文引用的文献

1
Dabigatran versus warfarin in patients with atrial fibrillation.达比加群与华法林用于房颤患者的比较。
N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30.
2
Mechanisms for the genesis of paroxysmal atrial fibrillation in the Wolff Parkinson-White syndrome: intrinsic atrial muscle vulnerability vs. electrophysiological properties of the accessory pathway.预激综合征中阵发性心房颤动的发生机制：心房肌固有易损性与旁路电生理特性
Europace. 2008 Mar;10(3):294-302. doi: 10.1093/europace/eun031.
3
Newly detected atrial fibrillation and compliance with antithrombotic guidelines.新检测出的心房颤动与抗血栓指南的依从性
Arch Intern Med. 2007 Feb 12;167(3):246-52. doi: 10.1001/archinte.167.3.246.
4
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.明尼苏达州奥姆斯特德县1980年至2000年心房颤动发病率的长期趋势及其对未来患病率预测的影响。
Circulation. 2006 Jul 11;114(2):119-25. doi: 10.1161/CIRCULATIONAHA.105.595140. Epub 2006 Jul 3.
5
Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation.华法林在医疗保险受益人心房颤动患者中的使用及有效性
Stroke. 2006 Apr;37(4):1070-4. doi: 10.1161/01.STR.0000208294.46968.a4. Epub 2006 Mar 9.
6
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.心房颤动的患病率、发病率和终生风险：鹿特丹研究。
Eur Heart J. 2006 Apr;27(8):949-53. doi: 10.1093/eurheartj/ehi825. Epub 2006 Mar 9.
7
Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.在非瓣膜性心房颤动患者中使用口服直接凝血酶抑制剂希美加群预防中风。SPORTIF III和V研究的汇总分析。
Cerebrovasc Dis. 2006;21(4):279-93. doi: 10.1159/000091265. Epub 2006 Jan 5.
8
Influence of advancing age on fractionated right atrial endocardial electrograms.年龄增长对右心房内膜电图分段的影响。
Am J Cardiol. 2005 Jul 15;96(2):239-42. doi: 10.1016/j.amjcard.2005.03.052.
9
Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis.华法林抗凝治疗与心房颤动患者的预后：一项系统评价和荟萃分析。
Chest. 2004 Dec;126(6):1938-45. doi: 10.1378/chest.126.6.1938.
10
Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.心房颤动的抗栓治疗：第七届美国胸科医师学会抗栓与溶栓治疗会议
Chest. 2004 Sep;126(3 Suppl):429S-456S. doi: 10.1378/chest.126.3_suppl.429S.

Dabigatran, A Direct Thrombin Inhibitor, In Atrial Fibrillation: Is It Already Time For A Change In Oral Anticoagulation Therapy?

作者信息

Centurión Osmar Antonio

机构信息

Division of Electrophysiology and Arrhythmias. Cardiovascular Institute. Sanatorio Migone-Battilana. Asunion,Paraguay. Departamento de Cardiología. Primera Cátedra de Clínica Médica. Universidad Nacional de Asución.

出版信息

J Atr Fibrillation. 2010 Jan 1;2(4):234. doi: 10.4022/jafib.234. eCollection 2010 Jan-Feb.

DOI:10.4022/jafib.234
PMID:28496648
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4956206/
Abstract
摘要